Peggy Scherle Biography and Net Worth

Insider of Prelude Therapeutics

Peggy Scherle, Ph.D. has served as Chief Scientific Officer at Prelude Therapeutics since 2018. Prior to joining Prelude, Dr. Scherle held several roles at Incyte Corporation, most recently serving as Group Vice President, Discovery Biology and Preclinical Pharmacology where she oversaw the target validation and preclinical drug discovery efforts. Her prior roles at Incyte included Vice President, Preclinical Pharmacology from 2014 until 2017 and as Executive Director, In Vitro Biology from 2011 until 2014. Dr. Scherle was one of the original team of scientists that joined Incyte in 2002 and was involved in the discovery and development of the JAK inhibitors, Jakafi® (ruxolitinib), for the treatment of myelofibrosis and polycythemia vera, and Olumiant® (baricitinib), for rheumatoid arthritis, as well as the advancement of >10 small molecules into clinical studies for cancer, including both targeted therapy and immunotherapy approaches. Prior to Incyte, Dr. Scherle held scientific research positions with DuPont Pharmaceuticals Company and Bristol- Myers Squibb. Dr. Scherle received her Ph.D. in immunology from the University of Pennsylvania and completed her postdoctoral training at the NIH.

What is Peggy Scherle's net worth?: The estimated net worth of Peggy Scherle is at least $15,998.32 as of April 7th, 2021. Dr. Scherle owns 15,383 shares of Prelude Therapeutics stock worth more than $15,998 as of November 16th. This net worth evaluation does not reflect any other assets that Dr. Scherle may own. Additionally, Dr. Scherle receives an annual salary of $868,620.00 as Insider at Prelude Therapeutics. Learn More about Peggy Scherle's net worth.
How old is Peggy Scherle?: Dr. Scherle is currently 62 years old. There are 4 older executives and no younger executives at Prelude Therapeutics. Learn More on Peggy Scherle's age.
What is Peggy Scherle's salary?: As the Insider of Prelude Therapeutics Incorporated, Dr. Scherle earns $868,620.00 per year. The highest earning executive at Prelude Therapeutics is Dr. Krishna Vaddi D.V.M., Ph.D., Founder, CEO & Director, who commands a salary of $905,920.00 per year. Learn More on Peggy Scherle's salary.
How do I contact Peggy Scherle?: The corporate mailing address for Dr. Scherle and other Prelude Therapeutics executives is , , . Prelude Therapeutics can also be reached via phone at 302-467-1280 and via email at [email protected]. Learn More on Peggy Scherle's contact information.
Has Peggy Scherle been buying or selling shares of Prelude Therapeutics?: Peggy Scherle has not been actively trading shares of Prelude Therapeutics during the past quarter. Most recently, Peggy Scherle sold 1,700 shares of the business's stock in a transaction on Thursday, August 26th. The shares were sold at an average price of $35.19, for a transaction totalling $59,823.00. Learn More on Peggy Scherle's trading history.
Who are Prelude Therapeutics' active insiders?: Prelude Therapeutics' insider roster includes Andrew Combs (EVP), David Mauro (Insider), Deborah Morosini (EVP), Christopher Pierce (EVP), Brian Piper (CFO), and Peggy Scherle (Insider). Learn More on Prelude Therapeutics' active insiders.

Peggy Scherle Insider Trading History at Prelude Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/26/2021	Sell	1,700	$35.19	$59,823.00
7/27/2021	Sell	20,000	$35.47	$709,400.00
5/7/2021	Sell	10,000	$40.82	$408,200.00
4/7/2021	Sell	15,370	$39.31	$604,194.70	15,383

Peggy Scherle Buying and Selling Activity at Prelude Therapeutics

Prelude Therapeutics Company Overview

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Today's Range

Now: $1.04

$1.00

$1.08

50 Day Range

MA: $2.13

$1.03

$5.38

2 Week Range

Now: $1.04

$1.00

$6.80

Volume

425,323 shs

Average Volume

161,966 shs

Market Capitalization

$57.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>

Peggy Scherle Biography and Net Worth

What is Peggy Scherle's net worth?

How old is Peggy Scherle?

What is Peggy Scherle's salary?

How do I contact Peggy Scherle?

Has Peggy Scherle been buying or selling shares of Prelude Therapeutics?

Who are Prelude Therapeutics' active insiders?